Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03052751 · ClinicalTrials.gov registry record · Phase 2
Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
A Phase 2 study, sponsored by UCB Biopharma S.P.R.L..
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT03052751 is a Phase 2 study that has completed, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 43 participants.
The verdict
NCT03052751, a Phase 2 study, has completed, sponsored by UCB Biopharma S.P.R.L..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the clinical efficacy of UCB7665 as a chronic-intermittent treatment in subjects with generalized myasthenia gravis (MG) who are classified as moderate to severe.
Interventions
- OTHER Placebo
- DRUG UCB7665
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2017-05-15 |
| Est. Completion | 2018-08-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03052751
The ClinicalTrials.gov registry entry for NCT03052751 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma S.P.R.L., which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03052751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03052751 about?
NCT03052751 is a clinical study titled "Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis". The purpose of the study is to evaluate the clinical efficacy of UCB7665 as a chronic-intermittent treatment in subjects with generalized myasthenia gravis (MG) who are classified as moderate to severe.
What is the current status of trial NCT03052751?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2017-05-15. Estimated completion is 2018-08-06.
What interventions are being tested in trial NCT03052751?
The interventions under investigation include: Placebo (OTHER), UCB7665 (DRUG).
Who is sponsoring clinical trial NCT03052751?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.